Skip to search formSkip to main contentSkip to account menu

CYC116

Known as: Aurora Kinase/VEGFR2 Inhibitor CYC116, CYC 116, CYC-116 
An orally bioavailable small molecule multi-kinase inhibitor with antineoplastic activity. Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
Highly Cited
2017
Highly Cited
2017
Differential Expression of VEGF‐Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis
Rationale: Fibrosis after lung injury is related to poor outcome, and idiopathic pulmonary fibrosis (IPF) can be regarded as an… 
Review
2017
Review
2017
Mimetic peptide of ubiquitin-interacting motif of epsin as a cancer therapeutic-perspective in brain tumor therapy through regulating VEGFR2 signaling
Epsins, endocytic adaptor proteins required for internalization of ubiquitylated receptors, are generally upregulated in human… 
2017
2017
VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens
VEGF , VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens 
2016
2016
Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.
Antiangiogenic tyrosine kinase inhibitors (TKI) that target VEGF receptor-2 (VEGFR2) have not been effective as adjuvant… 
Review
2015
Review
2015
Correlation between VEGFR2 rs2071559 polymorphism and glioma risk among Chinese population.
OBJECTIVE We investigated the correlation between vascular endothelial growth factor 2 (VEGFR2) polymorphism and glioma risk… 
2013
2013
Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy.
Drug resistance is the major obstacle to successful cancer therapy. Our study focuses on resistance to Aurora kinase inhibitors… 
Highly Cited
2010
Highly Cited
2010
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
Through cell-based screening of our kinase-directed compound collection, we discovered that a subset of N-phenyl-4-(thiazol-5-yl… 
2008
2008
In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2
5645 Aurora kinases are key regulators of mitosis and cytokinesis and their upregulation has been associated with tumour genesis… 
Highly Cited
2006
Highly Cited
2006
Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration
Angiogenesis following traumatic brain injuries (TBIs) may be of importance for post‐traumatic reparative processes and the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)